Episodes

  • The Degree Dividend: Mapping the Statistical Link Between Education and Dementia

    The Degree Dividend: Mapping the Statistical Link Between Education and Dementia
    May 25 2026
    Across decades of public health data, researchers have noticed a stunning trend: as global education rates climb, age-adjusted dementia numbers are beginning to drop. This episode breaks down the complex longitudinal studies tracking how even a single additional year of schooling correlates with a significantly delayed onset of cognitive decline. We analyze the variables at play, investigating whether degrees themselves protect the mind or if they simply act as a proxy for healthier lifelong habits.
    Show More Show Less
    7 mins
  • The Cellular Link: How Youth Obesity Triggers Early-Onset Malignancies

    The Cellular Link: How Youth Obesity Triggers Early-Onset Malignancies
    May 15 2026
    Recent epidemiological data shows a devastating rise in aggressive, early-onset cancers among adults who experienced metabolic dysfunction before age 30. This episode examines the precise biomolecular pathways—including hyperinsulinemia, altered cytokine signaling, and chronic systemic inflammation—that accelerate tumor development in adipose tissue environments. Join clinical researchers as they dissect the newest peer-reviewed oncology studies to understand how early-life obesity fundamentally alters cellular mutation rates.
    Show More Show Less
    8 mins
  • Sunscreen Efficacy: Weighing Evidence for Melanoma Prevention and Vitamin D Implications

    Sunscreen Efficacy: Weighing Evidence for Melanoma Prevention and Vitamin D Implications
    May 8 2026
    This podcast evaluates the scientific evidence supporting and questioning the role of sunscreen in melanoma prevention, drawing on randomized controlled trials, observational studies, and meta-analyses while addressing key limitations. It examines the interplay between sunscreen use and vitamin D synthesis, presenting arguments for potential interference alongside real-world data indicating minimal clinical impact. A balanced conclusion emphasizes evidence-based sun protection strategies tailored to individual risk profiles, particularly for high-risk ethnic groups in sunny environments.
    Show More Show Less
    6 mins
  • Surrogate Endpoints in Research Studies: Acceleration of Knowledge or Misleading Shortcuts?

    Surrogate Endpoints in Research Studies: Acceleration of Knowledge or Misleading Shortcuts?
    May 6 2026
    This podcast episode explores the use of surrogate endpoints versus patient-important clinical outcomes in medical and psychological research studies, highlighting their role in accelerating trials while cautioning against over-reliance. It presents advantages such as faster, less expensive studies alongside critical limitations, including frequent failures to predict real clinical benefit as seen in cardiovascular, oncology, and Alzheimer’s research. Listeners receive a balanced framework for critically appraising research that employs surrogate markers.
    Show More Show Less
    8 mins
  • Shrinking Brains or Just Shaky Science? Dissecting the Obesity-Dementia Link

    Shrinking Brains or Just Shaky Science? Dissecting the Obesity-Dementia Link
    May 5 2026
    We put the "obesity shrinks your brain" headlines under the microscope to separate causal reality from confounding variables. This episode navigates the neurodegeneration debate, questioning if the data holds up or if we're seeing another case of correlation being sold as causation. Join us as we strip away the spin to see what the evidence actually says about the relationship between weight and white matter.
    Show More Show Less
    6 mins
  • The MIT AI Myth: Debunking the "95% Failure" Stat That Shook Markets

    The MIT AI Myth: Debunking the "95% Failure" Stat That Shook Markets
    May 3 2026
    In 2025, a viral study claiming that 95% of corporate AI pilots were failing sent the Nasdaq into a tailspin—but there was one problem: the math was 100% wrong. We join Rob Wiblin to dissect how a flawed report managed to hijack the global AI narrative and what the evidence actually says about the success of generative AI in the enterprise. Learn how to spot "data torture" and why the real story of AI integration is far more optimistic than the headlines suggest.
    Show More Show Less
    6 mins
  • Vaping & Cancer: The 2026 Review – Real Risk or Overhyped Alarm?

    Vaping & Cancer: The 2026 Review – Real Risk or Overhyped Alarm?
    Apr 26 2026
    A major 2026 review in the journal Carcinogenesis claims nicotine vapes are “likely” to cause lung and oral cancers based on DNA damage, inflammation, and mouse tumors. Public-health experts on the other side call the paper misleading, arguing vaping remains far safer than smoking and a proven tool for quitting. We examine both arguments, expose the limitations of the studies on each side, and end with practical, no-nonsense advice for listeners.
    Show More Show Less
    7 mins
  • Science vs Spin: Do Anti-Amyloid Drugs Actually Work for Alzheimer’s? The Cochrane vs Lancet Debate

    Science vs Spin: Do Anti-Amyloid Drugs Actually Work for Alzheimer’s? The Cochrane vs Lancet Debate
    Apr 24 2026
    This episode examines the heated debate between the Cochrane Review and The Lancet on anti-amyloid drugs for Alzheimer’s. We break down the modest benefits, real risks, and methodological differences between older and newer treatments. A balanced, evidence-based analysis for patients, families, and clinicians seeking clarity on this controversial topic.
    Show More Show Less
    4 mins